Posters

Evaluation of visual quality in patients suffering from meibomian gland dysfunction after intense pulsed light treatment

Poster Details

First Author: M.Romero Sanz SPAIN

Co Author(s):    A. Blasco Martinez   E. Del Prado Sanz   J. Gutierrez Vasquez   G. Lopez Valverde   C. Almenara Michelena   A. Mateo Orobia     

Abstract Details

Purpose:

To evaluate changes in visual quality through different parameters analyzed by the OQAS (Optical Quality Analisis System) of patients suffering from evaporative Dry Eye Disease (DED) due to Meibomiam Gland Dysfunction (MGD) treated with Intense Pulsed Light (IPL).

Setting:

Hospital Miguel Servet and Hospital Royo Villanova, Zaragoza , Spain

Methods:

Nine patients (eighteen eyes) suffering from evaporative DED due to MGD, were selected. IPL treatment was applied in a total of three sessions per patient (days 0-15-45). At each visit, five flashes were performed in both periocular areas. In the pre-treatment visit, their baseline optical quality was measured with the OQAS. Intraocular dispersion values such as Objective Scatter Index (OSI), Strehl ratio, Modulation Transfer Function (MTF) and simulated visual acuity with 100%, 20% and 9% contrasts, were collected. Once concluded, the same values were re-recorded. Finally, the existence of significant differences between the pre- and post- treatment measurements was analyzed.

Results:

The mean of simulated visual acuity for contrast of 100%, 20% and 9% increased from (0.8±0.26, 0.77±0.24 and 0.8±0.23) to (1.03±0.28, 1.01±0.31 and 1.02±0.29) (p=0.002, p=0.001, p=0.009) respectively. The Strehl ratio changed from 0.14±0.03 to 0.17±0.03 meaning a decrease in aberrations (p=0.008). The MTF value increased from 24.16±8.04 to 31.05±8.56 (p=0.002) and the OSI value decreased from 1.39±0.67 to 0.88±0.44, confirming a lower intraocular scattering of light.

Conclusions:

IPL treatment achieves an improvement in different parameters that measure the visual quality of patients suffering from DED. Future studies including new ocular surface variables and larger sample size, would provide more information on the applicability of this technique as a treatment for DED due to MGD.

Financial Disclosure:

None